Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

In the latest trading session, Johnson & Johnson (JNJ) closed at $147.77, marking a +1.93% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.21%. Elsewhere ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a ... s long and varied history. Johnson & Johnson was founded ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Gifting allows recipients to access the article for free. The hair-care company Johnson Products is justly celebrated as the first Black-owned company to go public, leading to a listing on the ...

the leading global retail solutions portfolio of Johnson Controls (NYSE: JCI), will now offer select Indyme Solutions (Indyme) merchandise protection products in its loss prevention portfolio of ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC's Squawk on the ...